DB18240InvestigationalProtein Based Therapies
MK-2225: Overview.
- Also known as
- Homodimeric fragment crystallizable fusion protein comprised of the extracellular domain of the human transforming growth factor beta receptor type II linked to a human IgG1 Fc domain
- Code names
- ACE-1334 · MK-2225
Resolves to
Compound
What you can answer from here — as of April 23, 2025
Which companies are running trials of MK-2225, in which indications and phases, and which of those programs are still active?
Create a free account or log in to explore the full data card.
Create Account